WW domain binding protein 4Genealiases: FBP21 · NEDHFDB
Q-omics provides the consensus-scored WBP4 profile across patient tissues and cancer cell-line models. WBP4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WBP4 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, WBP4 protein abundance shows 25,655 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, THCA, and LSCC as cancer lineages where WBP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WBP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WBP4 survival associations across molecular data types. WBP4 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WBP4 RNA expression–survival associations across cancer types. High WBP4 expression shows unfavorable associations in CESC and HNSC, but favorable associations in KIRC, UCS, SKCM and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for WBP4 RNA expression.
This table summarizes WBP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for WBP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WBP4 shows lower tumor expression in THCA, KICH, LUAD, LUSC and BRCA and higher tumor expression in LIHC. The THCA box plot shows higher WBP4 RNA expression in normal versus tumor tissue (log2 FC = −0.440, t-test p < 0.001).
This table shows molecular features associated with WBP4 in patient tissues and cancer cell lines. In patient samples, WBP4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, WBP4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
